Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bioasis Technologies Inc.
Bullboard Posts
User Avatar Image
(163)
•••
Comment by Sniper007on Nov 28, 2013 8:12pm
151 Views
Post# 21951727

RE:RE:RE:RE:RE:RE:It's a start. First up day in 10

RE:RE:RE:RE:RE:RE:It's a start. First up day in 10The BT2111 tests have all been conducted on mice using the HUMAN protein P97 which is the basis used in our Transcend vector.  The likelyhood of it working in humans is a good bet.  The uptake will likely be greater as well.  With mice, the uptake was 6.6% (see Feb 7, 2012 news release).  6.6% could very well be enough for treating human brains but it could be 10% or greater. 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities